Search

Displaying results 4511 - 4520 of 9333 in total
  1. Drug

    MDX-214

    go.drugbank.com/drugs/DB06110
    Experimental

    It is developed for the treatment of EGF-R overexpressing cancers. … MDX-214 consists of recombinant human epidermal growth factor (EGF) genetically linked to a fully human antibody fragment that is designed to activate cytotoxic killing of cancer cells by immune effector

  2. Drug

    OT-551

    go.drugbank.com/drugs/DB05650
    Investigational

    OT-551 is a novel small molecule that is topically dosed in an eye drop and has the unique ability to penetrate cell membranes and reach both the front and the back of the eye. … degeneration (AMD) by protecting against retina photoreceptor cell death and inhibiting angiogenesis, the growth of small blood vessels leading to the wet-form of AMD.

  3. Drug

    3-Fluoro-L-tyrosine

    go.drugbank.com/drugs/DB04436
    Experimental

    This compound belongs to the phenylpropanoic acids. … These are compounds whose structure contain a benzene ring conjugated to a propanoic acid. 3-Fluoro-L-tyrosine targets the protein superoxide dismutase [mn], mitochondrial.

  4. Drug

    TEL540-548

    go.drugbank.com/drugs/DB17461
    Investigational

    TEL540-548 is a recombinant peptide consisting of the amino acid residues 540 to 548 of the human telomerase reverse transcriptase (hTERT).

  5. Drug

    Uridine monophosphate

    go.drugbank.com/drugs/DB03685
    Investigational

    A uracil nucleotide containing one phosphate group esterified to the sugar moiety in the 2', 3' or 5' position.

  6. Drug

    Motexafin lutetium

    go.drugbank.com/drugs/DB05296
    Investigational

    It belongs to the family of drugs called metallotexaphyrins. Also called lutetium texaphyrin. Motexafin lutetium is a pentadentate aromatic metallotexaphyrin with photosensitizing properties.

  7. Drug

    Human papillomavirus type 52 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10313
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 52 The vaccine is prepared from the purified virus-like particles … (VLPs) of the major capsid (L1) protein of HPV Type 52 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.

  8. Drug

    Iron sucrose

    go.drugbank.com/drugs/DB09146
    ApprovedInvestigational

    Due to less side effects than iron dextran, iron sucrose is more preferred in chronic kidney disease patients.

    International brands: Fe-backProducts: FE-BACK INJECTION 2% "N.K.", ENJEKSİYON VE İNFÜZYON İÇİN KONSANTRE ÇÖZELTİ İÇEREN AMPUL, 5 ADET
  9. Drug

    IMCY-0141

    go.drugbank.com/drugs/DB17019
    Investigational

    IMCY-0141 is a synthetic peptide based on MOG (Myelin Oligodendrocyte Glycoprotein), a dominant autoantigen, designed to stop the progression of multiple sclerosis (MS) and the destruction of the myelin … sheath protecting the nerves.

  10. Drug

    Sunvozertinib

    go.drugbank.com/drugs/DB18925
    Investigational

    [A274143] Sunvozertinib was granted accelerated approval in the US on July 2, 2025 for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor … [A40018] EGFR often have mutations that lead to unfavourable treatment options and prognosis.